Drug Profile
Research programme: microbiome-based therapeutics - Janssen Human Microbiome Institute/Weizmann Institute of Science
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Developer Janssen human microbiome institute; Weizmann Institute of Science
- Class
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified